Abandon biosimilars in favor of post-exclusivity regs on biologic prices, argue researchers

An alternative to biosimilars has been proposed as a means of bringing down the prices of off-patent biologics.

This view is expressed by four researchers, penning a blog post for Health Affairs, with their case being that biosimilars are not the answer to reducing the prices of costly biologics.

The post states: “We argue that unlike small molecules that are granted artificial monopolies, biologics are best described as natural monopolies. They are protected by barriers to entry stemming from the scientific uncertainty that arises from their structural complexity; these barriers are expensive, time-consuming and risky to breach.